Clinical trial
Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival
NCT03919461 is registered in ClinicalTrials.gov with Assaf-Harofeh Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Perioperative Use of a β-adrenergic Blocker, Propranolol, and a COX2 Inhibitor, Etodolac, in Patients Undergoing Resection With Curative Intent for Primary Colon and Rectal Cancer: Effect on Tumor Recurrence and Survival
- Lead sponsor
- Assaf-Harofeh Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- February 28, 2019
- Completion date
- February 28, 2027
- Enrollment
- 200 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.